GlassScriptPhysician profile
John M Hatlelid
NPI 1194796698
$4,382.54
in general payments reported to CMS, 2019-2025
37 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $113 · 2021: $404 · 2022: $928 · 2023: $1,883 · 2024: $698 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Travel and Lodging: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.26 |
| Travel and Lodging | $876.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,215.33 | 2023 | Linq II |
| Abbvie INC. | $640.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $325.95 | 2019-2025 | |
| Allergan, INC. | $320.84 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $208.62 | 2022-2024 | Xarelto, Ponvory |
| Acadia Pharmaceuticals INC | $175.82 | 2022-2024 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $138.44 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $134.40 | 2022-2024 | Rytary |
| Biohaven Pharmaceutical Holding Company LTD. | $116.38 | 2022 | |
| Amgen INC. | $102.73 | 2022-2023 | Aimovig |
| Ucb, INC. | $85.36 | 2022-2023 | Fintepla |
| Argenx US, INC. | $78.22 | 2023-2024 | Vyvgart Hytrulo |
| Nevro Corp. | $68.05 | 2022-2023 | Senza |
| Neurelis, INC. | $65.44 | 2023 | Valtoco |
| Abbott Laboratories | $60.89 | 2023-2024 | Infinity |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.33 | 2022-2023 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $53.06 | 2019-2023 | Austedo |
| Eisai INC. | $48.50 | 2022 | |
| Lundbeck LLC | $46.50 | 2023-2024 | Vyepti |
| Grifols USA, LLC | $45.32 | 2022 | |
| Acorda Therapeutics, INC | $44.33 | 2022 | |
| Genzyme Corporation | $32.37 | 2022 | |
| Upsher-Smith Laboratories LLC | $32.36 | 2022 | |
| Kyowa Kirin, INC. | $29.40 | 2022-2023 | Nourianz |
| Mdd US Operations, LLC | $27.34 | 2019 | |
| Pfizer INC. | $25.79 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $24.34 | 2022 | |
| Impel Pharmaceuticals INC. | $23.80 | 2023 | Trudhesa |
| Amicus Therapeutics, INC. | $21.77 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.20 | 2022 | |
| Sumitomo Pharma America, INC. | $20.02 | 2023 | Aptiom |
| Emd Serono, INC. | $19.16 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.70 | 2023 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $16.65 | 2022 | |
| Neurocrine Biosciences, INC. | $13.59 | 2019 | |
| Biogen, INC. | $12.41 | 2022 | |
| W. L. Gore & Associates, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hatlelid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.